Vistagen Therapeutics, Inc. (VTGN) SEC Filing 8-K Material Event for the period ending Wednesday, October 24, 2018

Vistagen Therapeutics, Inc.

CIK: 1411685 Ticker: VTGN

View differences made from one to another to evaluate Vistagen Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Vistagen Therapeutics, Inc..


Assess how Vistagen Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Vistagen Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Vistagen Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: VTGN
CIK: 1411685
Form Type: 8-K Corporate News
Accession Number: 0001654954-18-011619
Submitted to the SEC: Fri Oct 26 2018 4:21:17 PM EST
Accepted by the SEC: Fri Oct 26 2018
Period: Wednesday, October 24, 2018
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. New Agreement
  3. Other Events
  4. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: